Biotechnology Research Roadmap - Science and Innovation
Biotechnology Research Roadmap - Science and Innovation Biotechnology Research Roadmap - Science and Innovation
Table 3 below shows a list of research priority signals, which party industry see as responsible for investment and the industries that have specifically indicated a particular area as a priority. Table 3 Primary Industry Research Priorities Research signal Priority area for For Government R&D Investment Biosecurity Human health and welfare Biodiversity knowledge Pastoral, Horticulture, Forestry, Marine, Arable Food and Beverage Marine For Co-Investment New products (includes foods) Increase productivity Environmentally sustainable Industry development Animal health and welfare Food safety Arable, Food and Beverage, Forestry, Marine, Pastoral Pastoral, Horticulture, Arable, Forestry, Marine Pastoral, Arable, Forestry, Marine Pastoral Pastoral, Horticulture, Food and Beverage For Private Sector R&D Investment Develop industry tools and markets Horticulture, Pastoral Industry’s expectations of what it considers “public good research”, to be funded by government alone, is research into understanding and protecting our natural environment and the subsequent competitive advantages that this bestows on industry and enhancing the health status of New Zealanders. The areas where industry considers the research investment responsibility of the private sector alone are largely at the market driven end of the spectrum. This includes the development of industry tools and markets, for example, research to understand consumer attitudes and preferences. Industry considers that research into increasing primary production productivity, food safety, animal health and welfare, ensuring that industry develops in an environmentally sustainable way, and bearing the risk of investing in research into value-added product developments with as yet untested markets, should be undertaken as a co-investment between government and industry. This expectation has been borne out via a number of the research consortia recently established between government and industry groups. 26 Roadmaps for Science : biotechnology research
5 Biotechnology Research in New Zealand Section summary The government currently invests $195 million per annum on biotechnology research. At 25% of total government R&D investment this is proportionally the highest share of government funded biotechnology research in the OECD. There is roughly a 50-50 split between research supporting basic and basic-targeted research on the one hand, and more outcomes-focused applied research and support for commercialisation on the other. The relative size of this investment means that a number of research funding and investment agencies are involved in allocating research funding; the largest investment agency being the Foundation for RS&T (72%). The bulk of the government’s research investments are directed towards achieving economic outcomes – fuelling competitive advantages within existing industries and building completely new industries. Biotechnology research has benefited from recent new investments in “cross-institutional” research configurations, like the Centres for Research Excellence and Research Consortia schemes. An analysis of current research investments shows that: • New Zealand possesses world-class niches in biomedical research and drug development research. This research is mostly prioritised on the basis of research excellence. • Plant and animal biotechnology research is largely consolidated around the key species critical to New Zealand’s primary production sectors. • Opportunities exist to integrate underpinning research platforms in some areas. • Biotechnology research is critical to the value-added product end of food and nutrition research. A gap exists between the potentially transformational research being currently undertaken and industry’s ability to pick it up in the future. • Investments in marine biotechnology are comparatively low at 2% of the total. To capitalise from opportunities in this area there is a need to build both research capability and industry’s capacity to utilise research. • Industrial biotechnology offers future opportunities for research, but improved coordination is required to harness the value proposition for New Zealand. • Although the government has invested in social and environmental impacts research to support improved decision-making, end-user feedback indicates that there is fragmentation between research providers as well as a need for better strategic oversight of this area. Roadmaps for Science : biotechnology research 27
- Page 3 and 4: ROADMAPS forSCIENCE A GUIDE FOR NEW
- Page 5 and 6: Summary Biotechnology research has
- Page 7 and 8: Directions : ECONOMIC 1 The governm
- Page 9 and 10: 1.2 Scope of this Roadmap Since 200
- Page 11 and 12: The biotechnology industry has grow
- Page 13 and 14: 2.3 Future outlook 15 • cleaner,
- Page 15 and 16: 2.6 Biotechnology and society No te
- Page 17 and 18: The perception that this is a “su
- Page 19 and 20: Biomedicine is the major focus for
- Page 21 and 22: 3.4 A unique environment New Zealan
- Page 23 and 24: 4 The strategic landscape Section s
- Page 25 and 26: Food and Beverage Taskforce 50 The
- Page 27: 4.2 The biotechnology regulatory en
- Page 31 and 32: 5.2 Who is allocating biotechnology
- Page 33 and 34: Using these horizon categories, FRS
- Page 35 and 36: The core public sector biotechnolog
- Page 37 and 38: Current investment levels and trend
- Page 39 and 40: Proacta Therapeutics Proacta Therap
- Page 41 and 42: Figure 10 Animal biotechnology rese
- Page 43 and 44: Smart Sheep Science New Zealand is
- Page 45 and 46: Issues or gaps The impact of biotec
- Page 47 and 48: (Side Box) Case Study: ‘Nature Id
- Page 49 and 50: National Centre for Advanced Bio-pr
- Page 51 and 52: 6 Directions for Biotechnology Rese
- Page 53 and 54: Table 5 provides a summary of the s
- Page 55 and 56: Short-term actions: Research fundin
- Page 57 and 58: Short term actions: MoRST and New Z
- Page 59 and 60: 6.2.2 Directions: Environmental Dir
- Page 61 and 62: 6.2.3 Directions: Research to suppo
- Page 63 and 64: Direction 11 Greater focus on colla
- Page 65 and 66: Annex 1 References ABT Associates (
- Page 67 and 68: Annex 2 Continuum of public researc
- Page 69 and 70: Outcome-focused (Targeted Research)
- Page 71 and 72: Plant improvement Production of new
- Page 73 and 74: Biodiversity, Ecology & Evolution I
- Page 75 and 76: Government funded research by each
5 <strong>Biotechnology</strong> <strong>Research</strong><br />
in New Zeal<strong>and</strong><br />
Section summary<br />
The government currently invests $195 million per annum on biotechnology research. At 25% of total<br />
government R&D investment this is proportionally the highest share of government funded biotechnology<br />
research in the OECD.<br />
There is roughly a 50-50 split between research supporting basic <strong>and</strong> basic-targeted research on the one h<strong>and</strong>,<br />
<strong>and</strong> more outcomes-focused applied research <strong>and</strong> support for commercialisation on the other.<br />
The relative size of this investment means that a number of research funding <strong>and</strong> investment agencies are<br />
involved in allocating research funding; the largest investment agency being the Foundation for RS&T (72%).<br />
The bulk of the government’s research investments are directed towards achieving economic outcomes<br />
– fuelling competitive advantages within existing industries <strong>and</strong> building completely new industries.<br />
<strong>Biotechnology</strong> research has benefited from recent new investments in “cross-institutional” research<br />
configurations, like the Centres for <strong>Research</strong> Excellence <strong>and</strong> <strong>Research</strong> Consortia schemes.<br />
An analysis of current research investments shows that:<br />
• New Zeal<strong>and</strong> possesses world-class niches in biomedical research <strong>and</strong> drug development research. This<br />
research is mostly prioritised on the basis of research excellence.<br />
• Plant <strong>and</strong> animal biotechnology research is largely consolidated around the key species critical to New<br />
Zeal<strong>and</strong>’s primary production sectors.<br />
• Opportunities exist to integrate underpinning research platforms in some areas.<br />
• <strong>Biotechnology</strong> research is critical to the value-added product end of food <strong>and</strong> nutrition research. A gap<br />
exists between the potentially transformational research being currently undertaken <strong>and</strong> industry’s ability<br />
to pick it up in the future.<br />
• Investments in marine biotechnology are comparatively low at 2% of the total. To capitalise from<br />
opportunities in this area there is a need to build both research capability <strong>and</strong> industry’s capacity to utilise<br />
research.<br />
• Industrial biotechnology offers future opportunities for research, but improved coordination is required to<br />
harness the value proposition for New Zeal<strong>and</strong>.<br />
• Although the government has invested in social <strong>and</strong> environmental impacts research to support improved<br />
decision-making, end-user feedback indicates that there is fragmentation between research providers as<br />
well as a need for better strategic oversight of this area.<br />
<strong>Roadmap</strong>s for <strong>Science</strong> : biotechnology research<br />
27
Change language